Page 124 - Human Use News Today

Xeris Biopharma Holdings (NASDAQ:XERS) Inc has noted that Tetris Pharma - its commercialization partner for Ogluo in the UK, EEA, and Switzerland - is to be...

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agencys...

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agencys...

$75 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales from U.S. and Japan commercial launch; approval in Europe on...

Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include MonkeypoxCOPENHAGEN, Denmark, July 25, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission (EC) has extended the marketing authorization for the Company’s smallpox vaccine, IMVANEX® to...

$75 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales from U.S. and Japan commercial launch; approval in Europe on track for third quarter 2022 Biologics License Application

The Danish pharmaceutical company Bavarian Nordic Monday received the green light from the European Commission to use the Imvanex vaccine against monkeypox in the European Union, as well as in Iceland, Liechtenstein, and Norway.

A drug to treat a rare condition characterized by brain dysfunction has been recommended for marketing authorization.

AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The ...

Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox